Company: ZVRA
Filing Date: 2025-04-29
Form Type: DEFC14A
Source: 0000897069-25-000885
Chunk: 6

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-29
Form: DEFC14A
Chunk 6
---
 Banks and brokers call: 212-587-3005 Email: main@reganproxy.com 5 BACKGROUND OF THE SOLICITATION In April 2023, the Proponent’s director nominees, John B. Bode, Douglas W. Calder, and Corey Watton, were elected to the Board at the Company’s 2023 annual meeting, each receiving approximately 80% of the votes cast. The Proponent’s stockholder proposal to reverse any bylaw amendments from 2023 was also approved at the 2023 annual meeting, and received approximately 84% of the votes cast. The Proponent did not pay John B. Bode, Douglas W. Calder, or Corey Watton in connection with their nomination and there are no agreements, arrangements or understandings with respect to their positions as directors of the Company. On October 12, 2023, Neil F. McFarlane, the Company’s President, Chief Executive Officer, and a director, along with, R. LaDuane Clifton, the Company’s Chief Financial Officer and Treasurer, and Nichol Ochsner, the Company’s Vice President of Investor Relations and Corporate Communications, met with Mr. Mangless via teleconference to introduce Mr. McFarlane as the newly appointed Chief Executive Officer. On October 22, 2023, Mr. McFarlane and Ms. Ochsner met with Mr. Mangless via teleconference to discuss Mr. Mangless’ concerns with the Company’s operations, including his desire for Dr. Mickle, the Company’s former Chief Executive Officer, President, director, and co-founder, to work in a science-focused role with the Company. Dr. Mickle was replaced as Chief Executive Officer and had resigned, effective as of January 6, 2023, and as a director and the President of the Company, effective as of the date of the 2023 annual meeting. As part of the process of replacement and resignation, Dr. Mickle entered into a Transition Agreement and a Consulting Agreement, and continued to provide consulting services to the Company until October 31, 2024. Mr. Mangless additionally sought the Company to reimburse him for his expenses in connection with his solicitation of proxies for the proxy contest he initiated in connection with the 2023 annual meeting. As of the date hereof, the Company has not reimbursed Mr. Mangless for such expenses. On March 13, 2024, Mr. McFarlane met with Dr. Mickle via